Pre-challenge gut microbial signature predicts RhCMV/SIV vaccine efficacy in rhesus macaques
Hayden N. BrochuiD, Elise A. Smith, Sangmi JeongiD, Michelle C. CarlsoniD, Scott G. HanseniD, Jennifer Tisoncik-GoiD, G. Lynn LawiD, Louis J. PickeriD, Michael GaleiD, Xinxia PengiD
Abstract
BackgroundRhCMV/SIV vaccines protect [~]59% of vaccinated rhesus macaques against repeated limiting-dose intra-rectal exposure with highly pathogenic SIVmac239M, but the exact mechanism responsible for the vaccine efficacy is not known. It is becoming evident that complex interactions exist between gut microbiota and the host immune system. Here we aimed to investigate if the rhesus gut microbiome impacts RhCMV/SIV vaccine-induced protection. MethodsThree groups of 15 rhesus macaques naturally pre-exposed to RhCMV were vaccinated with RhCMV/SIV vaccines. Rectal swabs were collected longitudinally both before SIV challenge (after vaccination) and post challenge and were profiled using 16S rRNA based microbiome analysis. ResultsWe identified [~]2,400 16S rRNA amplicon sequence variants (ASVs), representing potential bacterial species/strains. Global gut microbial profiles were strongly associated with each of the three vaccination groups, and all animals tended to maintain consistent profiles throughout the pre-challenge phase. Despite vaccination group differences, using newly developed compositional data analysis techniques we identified a common gut microbial signature predictive of vaccine protection outcome across the three vaccination groups. Part of this microbial signature persisted even after SIV challenge. We also observed a strong correlation between this microbial signature and an early signature derived from whole blood transcriptomes in the same animals. ConclusionsOur findings indicate that changes in gut microbiomes are associated with RhCMV/SIV vaccine-induced protection and early host response to vaccination in rhesus macaques.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 0.15
- Field percentile
- 36th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Sustained IL-15 response signature predicts RhCMV/SIV vaccine efficacy
Fredrik Barrenäs, Scott G. Hansen, … Michael Gale·bioRxiv·Jan 11, 2021
- Combining a rhesus cytomegalovirus/SIV vaccine with neutralizing antibody to protect against SIV challenge in rhesus macaques
Jessica D. Coppola, Mara Parren, … Scott G. Hansen·Frontiers in MicrobiologyPeer-reviewed·Jun 2, 2025
- Gut-resident C. perfringens impedes rotavirus vaccine efficacy
Vu L. Ngo, Yanling Wang, … Andrew T. Gewirtz·bioRxiv·Jun 17, 2024
- Protection of rhesus macaques against vaginal SHIV challenges by VRC01 and an anti-α4β7 antibody
Giulia Calenda, Ines Frank, … Elena Martinelli·bioRxiv·Dec 11, 2018
- Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy
M. Verweij, S. G. Hansen, … K. Früh·bioRxiv·Sep 30, 2020
- Intranasal Delivery of HIV/SIV Antigens with NE/AS01B Adjuvants Enhances Cellular Immunity and Reduces Viral Loads in SHIV-Challenged Macaques
Michellie Thurman, Viswanathan Chokkavelu, … Siddappa N. Byrareddy·bioRxiv·Feb 5, 2026